Synthesis of elenic acid, an inhibitor of topoisomerase II

被引:20
|
作者
Hoye, RC [1 ]
Baigorria, AS [1 ]
Danielson, ME [1 ]
Pragman, AA [1 ]
Rajapakse, HA [1 ]
机构
[1] Macalester Coll, Dept Chem, St Paul, MN 55105 USA
来源
JOURNAL OF ORGANIC CHEMISTRY | 1999年 / 64卷 / 07期
关键词
D O I
10.1021/jo982260t
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
A short, efficient synthesis of elenic acid, a marine natural product with interesting biological activity, has been completed. Critical features of the synthesis are the development of methodology for the one-pot elaboration of an alkyne to an (E)-beta,gamma-unsaturated ester with a stereocenter at the alpha-position and the use of the zipper reaction of a 1-arylalkyne. This reaction has not been previously reported with aromatic substrates. The synthesis strategy provides considerable flexibility for the preparation of structural analogues.
引用
收藏
页码:2450 / 2453
页数:4
相关论文
共 50 条
  • [31] Inhibition of cellular proliferation by diterpenes, topoisomerase II inhibitor
    Miyata, S
    Wang, LY
    Yoshida, C
    Kitanaka, S
    BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (06) : 2048 - 2051
  • [32] Topoisomerase II inhibitor induced leukemia in a patient with AIDS
    Nabil, S
    Thomas, F
    Douglas, R
    Michael, B
    AIDS, 2001, 15 (03) : 421 - 423
  • [33] BERUBICIN: A NOVEL TOPOISOMERASE II INHIBITOR WITH ACTIVITY IN EPENDYMOMA
    Koul, Dimpy
    Fokt, Izabela
    Guan, Su
    Conrad, Charles A.
    Madden, Timothy
    Yung, W. K. Alfred
    Priebe, Waldemar
    NEURO-ONCOLOGY, 2009, 11 (05) : 640 - 640
  • [34] Etoposide: Four decades of development of a topoisomerase II inhibitor
    Hande, KR
    EUROPEAN JOURNAL OF CANCER, 1998, 34 (10) : 1514 - 1521
  • [35] THE ANTILEUKEMIC ALKALOID FAGARONINE IS AN INHIBITOR OF DNA TOPOISOMERASE-I AND TOPOISOMERASE-II
    LARSEN, AK
    GRONDARD, L
    COUPRIE, J
    DESOIZE, B
    COMOE, L
    JARDILLIER, JC
    RIOU, JF
    BIOCHEMICAL PHARMACOLOGY, 1993, 46 (08) : 1403 - 1412
  • [36] The homocamptothecin, BN 80927, is a potent topoisomerase I poison and topoisomerase II catalytic inhibitor
    Demarquay, D
    Coulomb, H
    Huchet, M
    Lesueur-Ginot, L
    Camara, J
    Lavergne, O
    Bigg, D
    CAMPTOTHECINS: UNFOLDING THEIR ANTICANER POTENTIAL, 2000, 922 : 301 - 302
  • [37] The combined effects of proteasome inhibitor bortezomib with topoisomerase I and II inhibitors on topoisomerase enzymes
    Oksuzoglu, Emine
    Tirinoglu, Ciydem
    Kerimoglu, Baris
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2016, 46 (06) : 1882 - 1888
  • [38] Ataxia telangiectasia mutated-dependent regulation of topoisomerase II alpha expression and sensitivity to topoisomerase II inhibitor
    Tamaichi, Hiroyuki
    Sato, Masaki
    Porter, Andrew C. G.
    Shimizu, Toshiaki
    Mizutani, Shuki
    Takagi, Masatoshi
    CANCER SCIENCE, 2013, 104 (02) : 178 - 184
  • [39] Phase I trial of the histone deacetylase inhibitor, valproic acid and the topoisomerase II inhibitor, epirubicin: A clinical and translational study.
    Munster, PN
    Marchion, DC
    Bicaku, E
    Sullivan, P
    Beam, C
    Mahany, JJ
    Lush, R
    Sullivan, DM
    Daud, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 212S - 212S
  • [40] Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamine acid
    Marchion, DC
    Bicaku, E
    Daud, AI
    Richon, V
    Sullivan, DM
    Munster, PN
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2004, 92 (02) : 223 - 237